Summary & Overview
HCPCS Q0512: Pharmacy Supply Fee for Subsequent 30-Day Oral Therapy
HCPCS Level II code Q0512 designates a pharmacy supply fee for a subsequent 30-day prescription of oral anti-cancer, oral anti-emetic, or immunosuppressive medications. The code is used in outpatient pharmacy and specialty pharmacy settings to capture an administrative or dispensing fee associated with follow-up prescriptions for oral systemic therapies. Nationally, accurate use of Q0512 matters for consistent billing of oral oncology and transplant-related medication management and supports cost tracking for oral treatment regimens outside the clinic setting.
Major payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of what the code represents, common payer coverage considerations, and the clinical contexts in which the code is applied. The publication summarizes benchmarking elements and policy-relevant issues related to pharmacy supply fees, clarifies typical sites of service, and outlines what information is commonly included on the service line for reporting these dispensing fees. Data not available in the input where specific payer policies, associated taxonomies, ICD-10 pairings, and related codes would normally be listed.
Billing Code Overview
HCPCS Level II code Q0512 describes a pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period. This code applies when a pharmacy supplies a follow-up 30-day prescription for covered oral oncology, anti-emetic, or immunosuppressive medications.
-
Service type: Pharmacy supply fee for oral systemic therapy prescriptions
-
Typical site of service: Outpatient retail or specialty pharmacy dispensing for patients receiving oral oncology, anti-emetic, or immunosuppressive therapies
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with metastatic colorectal cancer receives an oral targeted therapy dispensed by the clinic pharmacy. The first prescription in a 30-day period is billed separately; when the patient returns three weeks later for a refill within the same 30-day window, the clinic bills the pharmacy supply fee for a subsequent prescription using Q0512. The clinical workflow: the oncologist documents the indication and prescription in the electronic medical record, the clinic pharmacist verifies dosing and counseling, the medication is dispensed or shipped to the patient, counseling and side-effect monitoring are documented, and billing posts Q0512 to capture the pharmacy supply fee for the subsequent oral anti-cancer or oral anti-emetic prescription within the 30-day period. Typical sites of service include outpatient oncology clinics, hospital outpatient infusion centers with onsite pharmacy dispensing, and specialty pharmacy hubs contracted with the clinic.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when ancillary pharmacy services required substantially greater work, such as complex compounding or extended counseling beyond typical supply services. |